Reduced-Dose Radiation Therapy for Diffuse Large B-cell Lymphoma
(DLBCL Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This phase II study will evaluate whether a reduction in radiation dose and field size will maintain a high rate of local control while minimizing the risk of acute and late toxicity .Hypothesis: The radiation dose and treatment volume can be safely reduced from 30 Gy to 20 Gy while maintaining high rates of local control in patients who had a negative PET-CT scan following rituximab - containing chemotherapy.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your doctor.
Is reduced-dose radiation therapy generally safe for humans?
Research on various forms of radiation therapy, like image-guided radiotherapy (IGRT) and intensity-modulated radiotherapy (IMRT), shows that these treatments are generally safe, with some risk of side effects such as gastrointestinal and genitourinary issues. These techniques are designed to target cancer more precisely, which helps protect healthy tissue and reduce side effects.12345
How is reduced-dose radiation therapy unique for treating diffuse large B-cell lymphoma?
What data supports the effectiveness of reduced-dose radiation therapy for diffuse large B-cell lymphoma?
Radiation therapy has shown improvement in progression-free survival for diffuse large B-cell lymphoma, and a trial is testing if a reduced dose can maintain long-term outcomes. Additionally, advanced techniques like image-guided radiotherapy (IGRT) can precisely target tumors, potentially reducing side effects.610111213
Who Is on the Research Team?
Christopher Kelsey, MD
Principal Investigator
Duke Health
Are You a Good Fit for This Trial?
This trial is for adults with a type of cancer called diffuse large B-cell lymphoma. Participants must have completed certain chemotherapy, show no signs of cancer on recent PET-CT scans, and have adequate blood cell counts. Pregnant women and those with specific other lymphoma types or conditions that make radiation unsafe cannot join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Chemotherapy
Participants receive at least 3 cycles of rituximab-containing chemotherapy
Radiation Therapy
Participants receive 19.5-20Gy of radiation therapy in 1.5-2Gy fractions, 5 days per week
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Radiation Therapy
Radiation Therapy is already approved in European Union, United States, Canada, Japan, China, Switzerland for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Duke University
Lead Sponsor